NRG / GY035
Trial Overview
Official Title
A Randomized Phase III Trial of Carboplatin, Paclitaxel, and Pembrolizumab versus Carboplatin, Paclitaxel, and Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab and Bevacizumab in the Treatment of PMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer
Study Purpose
To find out if adding a drug that blocks cancer blood vessel growth (bevacizumab) to the usual approach of paclitaxel and carboplatin with or without pembrolizumab immunotherapy lowers the chance of endometrial cancer growing or spreading.
Diagnosis
Endometrioid, serous, dedifferentiated/undifferentiated, clear cell, mixed epithelial, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.) endometrial cancer.Eligibility
Stage III or IV newly diagnosed or recurrent/progressed endometrial cancer, tumoral mismatch repair proficient and aberrant p53. No prior antiangiogenic therapy (bevacizumab) or anti-PD1, anti-PDL1 or anti-CTLA4 therapy.
Intervention
Arm 1: Paclitaxel + Carboplatin + Pembrolizumab
Arm 2: Paclitaxel + Carboplatin + Bevacizumab
Arm 3: Paclitaxel + Carboplatin + Pembrolizumab + Bevacizumab
For more information, click the link below:
https://clinicaltrials.gov/study/NCT07198074?term=nrg%20gy035&rank=1